OncLive Peer Exchange®

A panel of esteemed physicians review recent key data updates in ovarian cancer from ESMO 2022, including late-breaking news.

A multidisciplinary panel discusses recent updates and advances in molecular testing and treatment for stage I-IIIA non-small cell lung cancer (NSCLC).

Centering discussion on clinical trial data and real-world patient profiles, expert oncologists review the treatment paradigm for hepatocellular carcinoma and consider how they would sequence therapy.

In the context of recent and ongoing clinical trials, expert oncologists provide comprehensive insight to the evolving treatment landscape of both clear cell and non–clear cell advanced RCC.

A global panel of experts discusses several recent data updates on the role of immunotherapy in non-small cell lung cancer (NSCLC) and their impact on clinical practice.

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

Expert panelists share insight on factors that lead to disparities in the management of multiple myeloma among racial and ethnic minority groups and strategies to address these disparities.

Expert panelists review the current treatment landscape of biliary tract cancers and consider how the field may evolve in light of novel therapeutic strategies in the pipeline.

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

A panel of experts discusses molecular testing and the use of targeted agents in lung and breast cancers, including best practices for ordering testing and how to factor results into treatment decisions.

A panel of experts in oncology review the use of antibody drug conjugates (ADCs) in breast and gastric cancers, defining optimal management of ADC-related adverse events.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®

A distinguished panel of experts in hematologic malignancies builds a lively discussion on recent clinical trials and potential advancements in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Expert panelists elucidate the evolving field of graft versus host disease management, highlighting novel therapies and treatment approaches.

Expert panelists review new data on the management of immune thrombocytopenia and consider how these data may impact clinical practice.

A panel of experts discusses newly presented data from ASCO 2022 and how it affects potential treatment approaches for relapsed/refractory DLBCL.

Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.

An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.

Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.

Expert oncologists Benjamin Levy, MD; Chaitali Nangia, MD; Jessica Donington, MD; Jonathan Wesley Riess, MD; Alexander Spira, MD; and Heather Wakelee, MD, review data from ASCO 2022 and updates in the management of NSCLC.

Expert oncologists Evan Y. Yu, MD; Andrew J. Armstrong, MD, MSc; Pedro C. Barata, MD, MSc; Tanya B. Dorff, MD; and Mary-Ellen Taplin, MD, review data from ASCO 2022 and discuss updates on the management of prostate cancer.

A panel of experts discuss how recent data from ASCO 2022 has changed the treatment landscape for small cell lung cancer.

Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.

Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.

A panel of expert oncologists discusses updates in advanced non-small cell lung cancer and the evolving treatment landscape, and its impact on clinical practice.

Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.

Expert panelists share insight on recent updates in the management of prostate cancer presented at several key conferences.

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

Experts in gastrointestinal cancers review recent updates to the treatment landscape of advanced HCC and share insights on their impact on clinical practice.

Expert panelists reflect on the evolving landscape of HER2+ metastatic breast cancer by discussing the latest research and recent clinical trials.

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.